08.4 · Pharma & healthcare¶
Sector playbook. Indian pharma is several businesses wearing one label: a domestic branded-generics market with FMCG-like economics, a US generics export business that swings with price erosion and FDA inspections, a fast-growing contract-manufacturing (CDMO) segment riding "China+1", an API industry, and — separately — hospitals and diagnostics with their own metrics. Analysing "a pharma company" means first decomposing it into these segments and applying the right lens to each.
Time: ~80 min · Prerequisites: 05.2 Industry analysis, 07.3 Cyclicals
1. How the industry makes money¶
| Segment | Model | Margin | Growth driver | Risk |
|---|---|---|---|---|
| Domestic formulations (branded generics) | Prescription brands sold via medical reps to doctors; chronic (diabetes, cardiac) vs acute (antibiotics, pain) | EBITDA 25–35%; gross 65–75% | Volume + price (limited by DPCO on scheduled drugs) + new launches; chronic share rising | Price control (NLEM/DPCO); trade generics; regulatory changes to prescribing |
| US generics | ANDA approvals; launch on patent expiry; first-to-file (180-day exclusivity) for Para IV; price competition among 5–15 players per molecule | EBITDA 15–25% (volatile) | Patent cliff pipeline; complex generics/injectables/specialty where competition is thinner | Price erosion (high-single to double digits in 2017–22; low-single-digit to flat by 2024–26 for many, but still high in crowded molecules — ICRA); USFDA compliance (Form 483s, warning letters, import alerts) |
| Specialty / branded (US, EU) | Own branded products (dermatology, ophthalmology, oncology) with sales forces | Can reach 30%+ once scaled; heavy upfront R&D and SG&A | Launches; label expansions | Trial failures; payer pushback |
| CDMO / CRDMO | Contract development and manufacturing for innovators (small molecules, peptides, biologics, ADCs) | EBITDA 25–35% at scale; lumpy | China+1 diversification; US BIOSECURE-type policies; innovator outsourcing | Customer concentration; project timing; capacity build-outs ahead of contracts |
| APIs / intermediates | Bulk drug manufacturing; commodity to complex | EBITDA 15–25%; cyclical | Regulatory approvals; China supply dynamics; PLI for KSMs | Chinese pricing; environmental compliance |
| Hospitals | Beds; case mix; occupancy; ARPOB | EBITDA 18–25% for mature networks | Bed additions; occupancy; ARPOB (case mix, international patients); insurance penetration | Regulatory price caps (pending proposals); doctor attrition; capex cycles |
| Diagnostics | Test volumes × realisation; B2B vs B2C; franchise collection centres | EBITDA 25–30% (down from 40%+ pre-2021 competition) | Volumes; premium tests; consolidation | Price competition from new entrants; test-price transparency |
| Health insurance | See 07.2 |
2. KPIs¶
| Segment | KPIs | Where |
|---|---|---|
| Domestic | Growth vs IPM (Indian pharma market, per IQVIA/AIOCD-AWACS); chronic share; market share by therapy; new launches; MR productivity; DPCO exposure (% of sales under price control) | Presentations; IQVIA data cited |
| US generics | US revenue ($ mn, per quarter); ANDA filings/approvals/pending; price erosion commentary; launches; Para IV pipeline; FDA inspection status by plant (last inspection date, outcome); share of complex/injectable/specialty | Presentations; FDA databases (warning letters, import alerts, 483s via FOIA) |
| CDMO | Order book / contracted revenue; number of molecules in pipeline by phase; capacity utilisation; customer count and concentration; capex plans | Presentations; concalls |
| API | Volumes; realisations; regulatory filings (DMFs, CEPs) | |
| Hospitals | Beds (operational vs capacity); occupancy; ARPOB (average revenue per occupied bed per day); ALOS (average length of stay); EBITDA per bed; case mix; new bed pipeline | Presentations |
| Diagnostics | Test volumes; patients; revenue per patient/test; B2B share; collection centres | Presentations |
3. What drives earnings and multiples¶
- Domestic: steady 8–12% market growth; chronic-heavy portfolios grow faster and command higher multiples; price control expansions (NLEM revisions) and the trade-generics push are the regulatory swing factors.
- US: the price-erosion cycle. After brutal erosion in 2017–22, pricing found a floor by 2024–26 as competitors exited and shortages emerged; margins recovered, then investors debated whether it lasts (Business Today). The other swing is FDA compliance: a warning letter or import alert on a major plant removes a year or more of launches — the single most common reason an Indian pharma stock halves.
- Trade policy: US tariff threats on pharma imports (2025–26) and any India–US trade deal outcomes; verify the current position, since it moves the whole export cohort.
- CDMO: the China+1 narrative drove multiples to 40–60x for the leaders (Divi's, Syngene, Laurus, Neuland, Piramal Pharma — verify); the cycle depends on innovator R&D budgets, biotech funding and policy (BIOSECURE).
- Hospitals: bed additions and ARPOB growth (8–12% a year) with high incremental margins; multiples of 20–30x EV/EBITDA for the leaders reflect the runway; risk is government price regulation.
- Multiples: domestic-heavy companies 25–35x; US-heavy generics 15–25x (cyclical); CDMO 35–60x; hospitals 20–30x EV/EBITDA; diagnostics de-rated from 60x+ to 30–40x after 2021 competition. Sum-of-segments valuation is the norm for diversified companies.
4. Accounting quirks¶
R&D expensed (Ind AS 38 allows capitalisation of development only after technical/commercial feasibility — most Indian pharma expenses it; compare R&D as % of sales); milestone and licensing income lumpy in other operating revenue; inventory write-downs on failed launches; litigation provisions (US patent and antitrust cases — contingent liabilities can be large); acquisition accounting for brand portfolios (intangibles amortised, often "adjusted" out of EPS); Ind AS 116 for hospitals (leased buildings); hospitals' capital-work-in-progress for new units and pre-opening losses.
5. Red flags¶
FDA inspection outcomes not disclosed promptly; a plant with repeated 483s supplying most US revenue; US revenue guided up while ANDA approvals stall; domestic growth "in line with IPM" while chronic share falls; CDMO capex far ahead of contracted revenue; related-party API sourcing; hospital ARPOB rising only through mix toward international patients; receivables from government schemes (Ayushman Bharat) building at hospitals; diagnostics volume growth from low-margin B2B while realisation falls; promoter actions (pledges, group companies in unrelated businesses) — several mid-cap pharma governance episodes in 2018–24 are worth reading.
6. How to value¶
Sum of segments: domestic on a DCF or P/E with a consumer-like fade; US generics on normalised margins (07.3 logic — price erosion is the cycle) with an explicit FDA-event scenario; specialty on risk-adjusted NPV of products; CDMO on contracted growth with capex and customer concentration; hospitals on EV/EBITDA per bed and bed-addition DCF; diagnostics on P/E with competition scenario. Always run a reverse DCF on CDMO and hospital names — those are where the market's growth expectations are most demanding.
7. Representative companies (for study; verify)¶
Sun Pharma (domestic + US specialty), Dr Reddy's, Cipla, Lupin, Aurobindo, Zydus, Torrent (domestic-heavy), Alkem, Mankind, JB Chemicals, Eris (domestic); Divi's, Syngene, Laurus Labs, Neuland, Piramal Pharma, Suven, Anthem Biosciences (CDMO/API); Gland Pharma (injectables); Apollo Hospitals, Max Healthcare, Fortis, Narayana Hrudayalaya, KIMS, Medanta (hospitals); Dr Lal PathLabs, Metropolis, Vijaya Diagnostics (diagnostics); Star Health, Niva Bupa (health insurance).
8. The 10-question sector checklist¶
- Segment split: how much profit is domestic, US, CDMO, other — and which lens applies to each?
- Domestic: growth vs IPM, chronic share, DPCO exposure?
- US: price-erosion trend, launch pipeline, and the FDA status of every plant that supplies the US?
- Trade policy: exposure to tariffs or trade deals?
- R&D: % of sales, split by generics/specialty/biosimilars, expensed or capitalised?
- CDMO: contracted revenue vs capex, customer concentration, phase mix?
- Hospitals: occupancy, ARPOB, bed pipeline, regulatory price-cap risk?
- Litigation and contingent liabilities (US patent/antitrust)?
- Governance: promoter group, related-party manufacturing, past regulatory actions?
- What does the multiple imply for growth and margins in each segment, and which segment carries the risk?
← Previous: 08.3 Consumer · Module index · Next: 08.5 Industrials, capital goods & defence →